Pfizer reports that its quarterly profit exceeds Wall Street expectations, citing strong demand for its blood thinner Eliquis alongside cost-management efforts. Multiple outlets describe the performance as driven by ongoing worldwide demand for Eliquis, which supports higher sales and helps the company deliver better-than-expected earnings. Business Line and Yahoo Finance both reference Pfizer’s quarterly results on an adjusted basis, with profit reported at 77 cents per share. NDTV similarly attributes the outperformance to surging Eliquis sales and highlights cost-management initiatives as an additional factor behind the results. The sources agree that Eliquis remains a key contributor to Pfizer’s financial performance in the quarter, reflecting continued demand for the therapy. Overall, Pfizer’s reported adjusted profit indicates the company clears analyst expectations, with the combination of strong product demand and internal efforts to manage expenses driving the results. The coverage does not provide additional figures beyond the adjusted per-share profit and the qualitative drivers noted above.